Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Bank of America Corporation from $105.00 to $120.00. They now have a "buy" rating on the stock.
Biotech Bill Bundled in Pentagon Spending Plan May Worsen Pharma's Patent Cliff Dilemma [Yahoo! Finance]
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - SNS Insider [Yahoo! Finance]
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE? [Yahoo! Finance]
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Morgan Stanley from $100.00 to $102.00. They now have an "equal weight" rating on the stock.